Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações do UNIOESTE |
Texto Completo: | http://tede.unioeste.br/handle/tede/3503 |
Resumo: | The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years. |
id |
UNIOESTE-1_63792ef53b8fee9983fc070b8b752ea2 |
---|---|
oai_identifier_str |
oai:tede.unioeste.br:tede/3503 |
network_acronym_str |
UNIOESTE-1 |
network_name_str |
Biblioteca Digital de Teses e Dissertações do UNIOESTE |
repository_id_str |
|
spelling |
Sanches, Andréia Cristina Conegerohttp://lattes.cnpq.br/9706216109598342Silva, Edson Antonio Alves dahttp://lattes.cnpq.br/0072529471507216Gandra, Rinaldo Ferreirahttp://lattes.cnpq.br/1550489676841150Pontarolo, Robertohttp://lattes.cnpq.br/1779931169656381Melo, Eduardo Borges dehttp://lattes.cnpq.br/0732955060928431http://lattes.cnpq.br/2799126783360313Taguti, Érika2018-03-09T19:11:50Z2014-12-17TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014.http://tede.unioeste.br/handle/tede/3503The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years.Os objetivos dessa pesquisa foram atualizar as revisões sistemáticas existentes de estudos econômicos parciais e completos da linezolida e descrever a economia de recursos com a hipotética troca da via de administração do medicamento (endovenosa para oral ou sonda nasoenteral) entre pacientes tratados em um hospital público. Foi conduzida uma revisão sistemática de estudos com os termos “clinical outcomes”, “cost analysis”, “economic outcomes” e “pharmacoeconomic studies” e “linezolid”, nas bases de dados Cochrane, IPA, Medline e Scopus, associado a busca manual. Também foi conduzida uma análise de custo-minimização entre pacientes hospitalizados que utilizaram as formas oral e/ou endovenosa de linezolida entre agosto de 2009 e agosto de 2013 em um hospital público paranaense. As pesquisa foram apresentadas em três diferentes artigos. Para a revisão sistemática foram encontrados 1352 artigos, sendo que 24 preencheram os critérios de inclusão para a revisão sistemática de estudos econômicos parciais e 43 para a revisão sistemática de avaliações econômicas completas. No geral, a linezolida mostrou melhores resultados clínicos e econômicos frente a antimicrobianos como vancomicina, daptomicina, teicoplanina, especialmente nos casos de pacientes com pneumonia, infeções de pele e tecidos moles e infeções por Staphylococcus aureus resistente a meticilina, para estudos econômicos parciais e completos, sendo um dos motivos relacionados à troca da via de administração endovenosa para oral. No estudo de custo-minimização, foram avaliados os prontuários de 152 pacientes, sendo 103 (67,8%) deles foram tratados com linezolida exclusivamente pela via endovenosa e em 33 (31,7%) oportunidades poderia ter ocorrido a troca para a forma oral de administração do antimicrobiano. O custo médio por paciente após a troca hipotética seria significativamente menor do que o valor real gasto (p<0,01) e a economia seria de R$ 32.680,03 em quatro anos.Submitted by Neusa Fagundes (neusa.fagundes@unioeste.br) on 2018-03-09T19:11:49Z No. of bitstreams: 2 Érica_Taguti2014.pdf: 1522601 bytes, checksum: 0c0c5940962174392fdd910bcc90e985 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2018-03-09T19:11:50Z (GMT). No. of bitstreams: 2 Érica_Taguti2014.pdf: 1522601 bytes, checksum: 0c0c5940962174392fdd910bcc90e985 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-12-17Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESapplication/pdfpor6588633818200016417500Universidade Estadual do Oeste do ParanáCascavelPrograma de Pós-Graduação em Ciências FarmacêuticasUNIOESTEBrasilCentro de Ciências Médicas e Farmacêuticashttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAntibióticosCusto efetividadeCusto-utilidadeFarmacoeconomiaHospitalAntibioticsCost effectivenessCost-utilityPharmacoeconomicsHospitalFARMACIA::ANALISE E CONTROLE E MEDICAMENTOSAvaliação do uso de linezolida: revisão sistemática e estudo de custo-minimizaçãoAssesment of linezolid use: a systematic review and cost-minimization studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesis7878055067573953101600600600600-894043971338784926762160250746569323362075167498588264571reponame:Biblioteca Digital de Teses e Dissertações do UNIOESTEinstname:Universidade Estadual do Oeste do Paraná (UNIOESTE)instacron:UNIOESTEORIGINALÉrica_Taguti2014.pdfÉrica_Taguti2014.pdfapplication/pdf1522601http://tede.unioeste.br:8080/tede/bitstream/tede/3503/5/%C3%89rica_Taguti2014.pdf0c0c5940962174392fdd910bcc90e985MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://tede.unioeste.br:8080/tede/bitstream/tede/3503/2/license_url4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80http://tede.unioeste.br:8080/tede/bitstream/tede/3503/3/license_textd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80http://tede.unioeste.br:8080/tede/bitstream/tede/3503/4/license_rdfd41d8cd98f00b204e9800998ecf8427eMD54LICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://tede.unioeste.br:8080/tede/bitstream/tede/3503/1/license.txtbd3efa91386c1718a7f26a329fdcb468MD51tede/35032018-03-09 16:11:50.062oai:tede.unioeste.br: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Biblioteca Digital de Teses e Dissertaçõeshttp://tede.unioeste.br/PUBhttp://tede.unioeste.br/oai/requestbiblioteca.repositorio@unioeste.bropendoar:2018-03-09T19:11:50Biblioteca Digital de Teses e Dissertações do UNIOESTE - Universidade Estadual do Oeste do Paraná (UNIOESTE)false |
dc.title.por.fl_str_mv |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
dc.title.alternative.eng.fl_str_mv |
Assesment of linezolid use: a systematic review and cost-minimization study |
title |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
spellingShingle |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização Taguti, Érika Antibióticos Custo efetividade Custo-utilidade Farmacoeconomia Hospital Antibiotics Cost effectiveness Cost-utility Pharmacoeconomics Hospital FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS |
title_short |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
title_full |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
title_fullStr |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
title_full_unstemmed |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
title_sort |
Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização |
author |
Taguti, Érika |
author_facet |
Taguti, Érika |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Sanches, Andréia Cristina Conegero |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/9706216109598342 |
dc.contributor.advisor-co1.fl_str_mv |
Silva, Edson Antonio Alves da |
dc.contributor.advisor-co1Lattes.fl_str_mv |
http://lattes.cnpq.br/0072529471507216 |
dc.contributor.referee1.fl_str_mv |
Gandra, Rinaldo Ferreira |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/1550489676841150 |
dc.contributor.referee2.fl_str_mv |
Pontarolo, Roberto |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/1779931169656381 |
dc.contributor.referee3.fl_str_mv |
Melo, Eduardo Borges de |
dc.contributor.referee3Lattes.fl_str_mv |
http://lattes.cnpq.br/0732955060928431 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/2799126783360313 |
dc.contributor.author.fl_str_mv |
Taguti, Érika |
contributor_str_mv |
Sanches, Andréia Cristina Conegero Silva, Edson Antonio Alves da Gandra, Rinaldo Ferreira Pontarolo, Roberto Melo, Eduardo Borges de |
dc.subject.por.fl_str_mv |
Antibióticos Custo efetividade Custo-utilidade Farmacoeconomia Hospital |
topic |
Antibióticos Custo efetividade Custo-utilidade Farmacoeconomia Hospital Antibiotics Cost effectiveness Cost-utility Pharmacoeconomics Hospital FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS |
dc.subject.eng.fl_str_mv |
Antibiotics Cost effectiveness Cost-utility Pharmacoeconomics Hospital |
dc.subject.cnpq.fl_str_mv |
FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS |
description |
The aims of this research were update systematic reviews available about partial and complete economic studies of linezolid and estimate differential cost between intravenous and oral administration with hypothetical linezolid switch therapy (intravenous to oral or nasogastric tube). A systematic review was conducted using the terms "clinical outcomes", "analysis cost", "economic outcomes" and "pharmacoeconomic studies" and "linezolid" in the databases Cochrane, IPA, Medline and Scopus, associated with manual search. It was also conducted a cost-minimization analysis among hospitalized patients who used oral and/or intravenous linezolid forms between August, 2009 and August, 2013 in a public hospital in southern Brazil. The research was presented in three different papers. For systematic review were found 1352 articles, of which 24 fulfilled inclusion criteria for the systematic review of partial economic studies and 43 for systematic review of complete economic evaluations. In general, linezolid showed better clinical and economic outcomes compared to antimicrobials such as vancomycin, daptomycin, teicoplanin, particularly in cases of pneumonia patients, infections of skin and soft tissues, infections of methicillin-resistant Staphylococcus aureus, for systematic review of partil and complete economic evaluations, due to the possibility switch therapy. In study of cost-minimization were evaluated records of 152 patients, 103 (67.8%) were treated with linezolid exclusively intravenous route and in 33 (31.7%) opportunities could have been the exchange to oral form administration of antimicrobial. The total cost per patient (mean) after changing from intravenous to oral administration was significantly lower than the real cost paid per patient (mean) (p<0.001). The cost savings associated with switching to oral linezolid administration would be US$14,328.32 over four years. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-12-17 |
dc.date.accessioned.fl_str_mv |
2018-03-09T19:11:50Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014. |
dc.identifier.uri.fl_str_mv |
http://tede.unioeste.br/handle/tede/3503 |
identifier_str_mv |
TAGUTI, Érika. Avaliação do uso de linezolida: revisão sistemática e estudo de custo-minimização. 2014. 120 f. Dissertação (Mestrado - Programa de Pós-Graduação em Ciências Farmacêuticas) - Universidade Estadual do Oeste do Paraná, Cascavel, 2014. |
url |
http://tede.unioeste.br/handle/tede/3503 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.program.fl_str_mv |
7878055067573953101 |
dc.relation.confidence.fl_str_mv |
600 600 600 600 |
dc.relation.department.fl_str_mv |
-8940439713387849267 |
dc.relation.cnpq.fl_str_mv |
6216025074656932336 |
dc.relation.sponsorship.fl_str_mv |
2075167498588264571 |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Estadual do Oeste do Paraná Cascavel |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UNIOESTE |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Centro de Ciências Médicas e Farmacêuticas |
publisher.none.fl_str_mv |
Universidade Estadual do Oeste do Paraná Cascavel |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações do UNIOESTE instname:Universidade Estadual do Oeste do Paraná (UNIOESTE) instacron:UNIOESTE |
instname_str |
Universidade Estadual do Oeste do Paraná (UNIOESTE) |
instacron_str |
UNIOESTE |
institution |
UNIOESTE |
reponame_str |
Biblioteca Digital de Teses e Dissertações do UNIOESTE |
collection |
Biblioteca Digital de Teses e Dissertações do UNIOESTE |
bitstream.url.fl_str_mv |
http://tede.unioeste.br:8080/tede/bitstream/tede/3503/5/%C3%89rica_Taguti2014.pdf http://tede.unioeste.br:8080/tede/bitstream/tede/3503/2/license_url http://tede.unioeste.br:8080/tede/bitstream/tede/3503/3/license_text http://tede.unioeste.br:8080/tede/bitstream/tede/3503/4/license_rdf http://tede.unioeste.br:8080/tede/bitstream/tede/3503/1/license.txt |
bitstream.checksum.fl_str_mv |
0c0c5940962174392fdd910bcc90e985 4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e bd3efa91386c1718a7f26a329fdcb468 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações do UNIOESTE - Universidade Estadual do Oeste do Paraná (UNIOESTE) |
repository.mail.fl_str_mv |
biblioteca.repositorio@unioeste.br |
_version_ |
1811723393299382272 |